For the 21st prioritisation (December 2014), 12 were filtered out of 169 identified drugs and were sent to prioritisation. Of these, 6 drugs were ranked as "highly relevant" by the expert panel, 5 as "relevant" and 1 as "not relevant". For "highly relevant" drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.